Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
celyvir (Hospital Universitario Niño Jesús)
- Development stage
- Unknown
- Lead developer
- Hospital Universitario Niño Jesús
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies, Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Celyvir is an autologous cell-based gene therapy consisting of bone marrow-derived mesenchymal stem cells (MSCs) infected with the oncolytic adenovirus ICOVIR5. Developed by the Hospital Infantil Universitario Niño Jesús in Madrid, it utilizes the natural tumor-homing capabilities of MSCs to deliver the oncolytic virus directly to metastatic and refractory solid tumors, effectively acting as a Trojan horse to bypass the host's immune system. Once at the tumor site, ICOVIR5 selectively replicates within and destroys cancer cells through viral lysis. This approach is primarily being evaluated in pediatric and adult patients with advanced malignancies, including neuroblastoma and various sarcomas, aiming to provide a targeted delivery system for oncolytic virotherapy.
- Other names
- ICOVIR5-infected mesenchymal stem cellsICOVIR-5-infected mesenchymal stem cellsICOVIR 5-infected mesenchymal stem cells
02
Targets
CXADR (Coxsackievirus and adenovirus receptor)αVβ3 (Integrin αVβ3)αVβ5 (Integrin αVβ5)
Beyond the preview
Go deeper on celyvir (Hospital Universitario Niño Jesús).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on celyvir (Hospital Universitario Niño Jesús).